Summary & Overview

HCPCS J0615: Calcium Acetate Oral 23 mg for ESRD on Dialysis

HCPCS Level II code J0615 denotes oral calcium acetate, 23 mg, intended for patients with end-stage renal disease (ESRD) on dialysis to manage hyperphosphatemia. This medication code is important nationally because phosphate binders are a routine component of dialysis care and influence medication management, drug coverage determinations, and dialysis formularies across payers.

Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J0615, typical sites of service, and the payer landscape relevant to coverage and billing. The publication also outlines available benchmarks and policy considerations affecting billing and reimbursement for dialysis-related oral medications.

This summary provides clinicians, billing professionals, and policy analysts with a clear description of what the code represents, where it is commonly administered, and which major payers are relevant. Data not available in the input are noted where applicable. The analysis emphasizes practical billing context, payer coverage scope, and clinical relevance for dialysis medication management nationally.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0615HCPCS Level IIcalcium acetateESRDdialysisphosphate binderoutpatient dialysismedication billing

Billing Code Overview

HCPCS Level II code J0615 represents calcium acetate, oral, 23 mg formulated for patients with end-stage renal disease (ESRD) on dialysis. The service type is oral medication for ESRD management, used to control serum phosphate levels in patients undergoing dialysis. The typical site of service is outpatient dialysis centers or inpatient dialysis units where ESRD patients receive dialysis and associated medication management.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with end-stage renal disease (ESRD) on maintenance hemodialysis presents for routine dialysis clinic follow-up. The nephrology team prescribes oral phosphate binder therapy to control hyperphosphatemia and reduce vascular calcification risk. The patient is prescribed calcium acetate, dosed as J0615 (calcium acetate, oral, 23 mg unit), to be taken with meals. Medication is dispensed by the dialysis clinic pharmacy and documented in the electronic medical record. The clinical workflow includes medication reconciliation at each dialysis visit, education by dialysis nursing on timing and adherence, monitoring of serum phosphorus and calcium at regular intervals, adjustments by the nephrologist based on laboratory trends, and documentation for billing using the J0615 HCPCS Level II code for supplies dispensed for ESRD patients on dialysis.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier.	Used when no special circumstances apply to the billed service.
`22`

Taxonomy Code	Specialty	Notes
`208000000X`	Nephrology	Nephrologists manage ESRD medications and phosphate binders.
`363L00000X`	Dialysis Facility	Dialysis clinics administer and coordinate outpatient medication dispensing for dialysis patients.
`367500000X`	Clinical Pharmacist	Pharmacists in dialysis units manage dosing, interactions, and patient counseling for phosphate binders.
`207Q00000X`	Internal Medicine	Primary care/internal medicine physicians co-manage chronic kidney disease and medication reconciliation.
`207K00000X`	Family Medicine	Family physicians often coordinate outpatient medication regimens for patients with ESRD.

ICD-10 Code	Description	Clinical Relevance
`N18.6`	End stage renal disease	Primary indication for use of phosphate binders like calcium acetate in patients on dialysis to manage hyperphosphatemia.
`E83.49`	Other disorders of phosphorus metabolism	Directly related to abnormal serum phosphate requiring management with phosphate binders.
`E78.5`	Hyperlipidemia, unspecified	Common comorbidity in ESRD patients; influences cardiovascular risk management alongside phosphate control.
`I70.9`	Atherosclerosis, unspecified	Vascular calcification risk is linked to disordered mineral metabolism; phosphate binders are part of mitigation strategy.
`M81.0`	Age-related osteoporosis without current pathological fracture	Altered calcium-phosphate balance in ESRD may affect bone health; calcium-containing binders impact calcium load.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes.	Commonly used for nephrology follow-up visits where medication management and adjustments for phosphate binders are performed.
`90935`	Hemodialysis procedure with single evaluation by a physician or other qualified health care professional, peritoneal dialysis exchange not included.	Represents the dialysis session context in which medication reconciliation and provision of `J0615` often occur.
`99406`	Smoking and tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes.	Ancillary counseling code that may be billed alongside medication management during an outpatient visit when applicable.
`99490`	Chronic care management services, at least 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.	May be billed when ongoing management of multiple chronic conditions, including ESRD and phosphate binder therapy, is provided.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.	Not directly related to oral `J0615` but included as a common allied procedure in dialysis clinics when injectable therapies are administered.

OpenPayer